Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Emily Wearne"'
Autor:
Katie Chon, Erin Larkins, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Stephanie Aungst, Emily Wearne, Sriram Subramaniam, Yangbing Li, Jiang Liu, Jielin Sun, Rosane Charlab, Hong Zhao, Banu Saritas-Yildirim, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clinical Cancer Research. :OF1-OF5
The FDA granted accelerated approval for amivantamab-vmjw (hereafter referred to as amivantamab), a bispecific antibody directed against EGFR and mesenchymal–epithelial transition receptor, on May 21, 2021, for the treatment of adult patients with
Autor:
Harpreet Singh, Julia A. Beaver, Marc R. Theoret, Richard Pazdur, Reena Philip, Soma Ghosh, Dun Liang, Hong Zhao, Jiang Liu, Rosane Charlab, Jielin Sun, Youwei Bi, Amal Ayyoub, Whitney S. Helms, Emily Wearne, Pallavi S. Mishra-Kalyani, Somak Chatterjee, Lee H. Pai-Scherf, Erin Larkins, Diana Bradford, Janice Kim
Supplementary Tables S1-S3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3e4b5d26de3d7ddf0a7029f07d3d7773
https://doi.org/10.1158/1078-0432.22481316.v1
https://doi.org/10.1158/1078-0432.22481316.v1
Autor:
Jingjing Ye, Lian Ma, Amy Barone, Nicholas Richardson, Emily Wearne, Kerry Jo Lee, Charu Gandotra
Publikováno v:
Drug Development for Rare Diseases ISBN: 9781003080954
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e632f57f35a182f7eb1f753a09792347
https://doi.org/10.1201/9781003080954-6
https://doi.org/10.1201/9781003080954-6
Autor:
Elizabeth S. Duke, Amy K. Barone, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Emasenyie Isikwei, Hong Zhao, Youwei Bi, Jiang Liu, Nam Atiqur Rahman, Emily Wearne, John K. Leighton, Maritsa Stephenson, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clin Cancer Res
On September 17, 2021, the U.S. Food and Drug Administration (FDA) approved cabozantinib (Cabometyx™; Exelixis, Inc.) for the treatment of adult and pediatric patients 12 years of age and older with locally advanced or metastatic differentiated thy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9c0ec5bde23f247a822bb3ecd816099e
https://europepmc.org/articles/PMC9529996/
https://europepmc.org/articles/PMC9529996/
Autor:
Elizabeth S. Duke, Liza Stapleford, Nicole Drezner, Anup K. Amatya, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Kimberly Maxfield, Jeanne Fourie Zirkelbach, Youwei Bi, Jiang Liu, Xinyuan Zhang, Hezhen Wang, Yuching Yang, Nan Zheng, Kelie Reece, Emily Wearne, Jacqueline J. Glen, Idara Ojofeitimi, Barbara Scepura, Abhilasha Nair, Rama Kamesh Bikkavilli, Soma Ghosh, Reena Philip, Richard Pazdur, Julia A. Beaver, Harpreet Singh, Martha Donoghue
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research.
On September 15, 2021, the FDA granted accelerated approval to mobocertinib (Exkivity, Takeda Pharmaceuticals USA, Inc.) for the treatment of adult patients with locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 in
Autor:
Janice Kim, Diana Bradford, Erin Larkins, Lee H. Pai-Scherf, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Emily Wearne, Whitney S. Helms, Amal Ayyoub, Youwei Bi, Jielin Sun, Rosane Charlab, Jiang Liu, Hong Zhao, Dun Liang, Soma Ghosh, Reena Philip, Richard Pazdur, Marc R. Theoret, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clinical Cancer Research. 27:5452-5456
The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non–small cell lung cancer (NSCLC) and December 1, 2020 for thyroid cancer, for: (i) adult patients with metastatic RET fusion–positive NSCLC, (ii) adult and pediatric
Autor:
Erica C. Nakajima, Nicole Drezner, Xiaoxue Li, Pallavi S. Mishra-Kalyani, Yajun Liu, Hong Zhao, Youwei Bi, Jiang Liu, Atiqur Rahman, Emily Wearne, Idara Ojofeitimi, Lauren Tesh Hotaki, Dianne Spillman, Richard Pazdur, Julia A. Beaver, Harpreet Singh
Publikováno v:
Clin Cancer Res
On May 28, 2021, the FDA granted accelerated approval to sotorasib (Lumakras, Amgen) for the treatment of adults with advanced non–small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C mutation who have received at le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::747866cb2c952dfd16c25124d4e235bc
https://europepmc.org/articles/PMC9012672/
https://europepmc.org/articles/PMC9012672/
Autor:
Janice, Kim, Diana, Bradford, Erin, Larkins, Lee H, Pai-Scherf, Somak, Chatterjee, Pallavi S, Mishra-Kalyani, Emily, Wearne, Whitney S, Helms, Amal, Ayyoub, Youwei, Bi, Jielin, Sun, Rosane, Charlab, Jiang, Liu, Hong, Zhao, Dun, Liang, Soma, Ghosh, Reena, Philip, Richard, Pazdur, Marc R, Theoret, Julia A, Beaver, Harpreet, Singh
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(20)
The FDA granted accelerated approval for pralsetinib on September 4, 2020 for non-small cell lung cancer (NSCLC) and December 1, 2020 for thyroid cancer, for: (i) adult patients with metastatic
Autor:
Hong Zhao, Steven Lemery, Erika Englund, Jingyu Yu, Patricia Keegan, Whitney S. Helms, Kun He, Leigh Marcus, Xianhua Cao, Sachia Khasar, Rajiv Agarwal, Emily Wearne, Olen Stephens, Weishi Yuan, Yaning Wang, Richard Pazdur
Publikováno v:
Clinical Cancer Research. 23:2924-2927
The FDA approved TAS-102 (Lonsurf; Taiho Oncology, Inc.) for the treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy; an anti-VEGF bio
Publikováno v:
Regulatory Toxicology and Pharmacology. 81:448-456
As sub-therapeutic doses are not medically justifiable in patients with cancer, we retrospectively analyzed data on immune activating products, to assess approaches used in first-in-human (FIH) dose selection, the utility of animal toxicology studies